Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Methyldopa
Drug ID BADD_D01425
Description Methyldopa, or α-methyldopa, is a centrally acting sympatholytic agent and an antihypertensive agent.[A231784] It is an analog of DOPA (3,4‐hydroxyphenylanine), and it is a prodrug, meaning that the drug requires biotransformation to an active metabolite for therapeutic effects. Methyldopa works by binding to alpha(α)-2 adrenergic receptors as an agonist, leading to the inhibition of adrenergic neuronal outflow and reduction of vasoconstrictor adrenergic signals.[A1499] Methyldopa exists in two isomers D-α-methyldopa and L-α-methyldopa, which is the active form.[A232224] First introduced in 1960 as an antihypertensive agent, methyldopa was considered to be useful in certain patient populations, such as pregnant women and patients with renal insufficiency. Since then, methyldopa was largely replaced by newer, better-tolerated antihypertensive agents;[A231784] however, it is still used as monotherapy [L32614] or in combination with [hydrochlorothiazide].[L32619] Methyldopa is also available as intravenous injection, which is used to manage hypertension when oral therapy is unfeasible and to treat hypertensive crisis.[L32624]
Indications and Usage For use in the treatment of hypertension.
Marketing Status Prescription; Discontinued
ATC Code C02AB01
DrugBank ID DB00968
KEGG ID D00405
MeSH ID D008750
PubChem ID 38853
TTD Drug ID D0BA6T
NDC Product Code 15894-0038; 42185-7001; 16729-031; 52423-0100; 16729-030; 67628-3001
Synonyms Methyldopa | alpha-Methyldopa | alpha Methyldopa | alpha-Methyl-L-Dopa | alpha Methyl L Dopa | Alphamethyldopa | Meldopa | Methyldopate | Dopegyt | Dopergit | Dopegit | Sembrina | Apo-Methyldopa | Apo Methyldopa | Dopamet | Aldomet | Hydopa | Nu-Medopa | Nu Medopa
Chemical Information
Molecular Formula C10H13NO4
CAS Registry Number 555-30-6
SMILES CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)N
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal distension07.01.04.001--
Abdominal pain07.01.05.0020.007059%
Acute hepatic failure09.01.03.0010.004911%Not Available
Agranulocytosis01.02.03.001--Not Available
Amenorrhoea21.01.02.001; 05.05.01.002--
Angina pectoris24.04.04.002; 02.02.02.002--
Aphthous ulcer07.05.06.002--Not Available
Arthralgia15.01.02.001--
Asthenia08.01.01.001--Not Available
Atrial septal defect03.07.02.002; 02.04.02.0090.009412%Not Available
Blood creatinine increased13.13.01.0040.009412%
Blood urea increased13.13.01.0060.004706%Not Available
Body temperature increased13.15.01.001--Not Available
Bradycardia02.03.02.002--Not Available
Breast enlargement21.05.04.001--Not Available
Cardiac arrest02.03.04.0010.001841%
Cardiac failure02.05.01.001--
Cardiac failure congestive02.05.01.002--Not Available
Coagulopathy01.01.02.0010.007059%Not Available
Colitis07.08.01.001--
Constipation07.02.02.001--
Depression19.15.01.001--
Dermatitis23.03.04.002--Not Available
Diarrhoea07.02.01.001--
Dilatation ventricular02.04.02.0260.004706%Not Available
Dizziness24.06.02.007; 17.02.05.003; 02.01.02.004--
Drug withdrawal syndrome neonatal19.07.02.012; 18.04.13.001; 08.06.02.0080.004706%Not Available
Dry mouth07.06.01.002--
Dyskinesia17.01.02.006--
Dyspnoea22.02.01.004; 02.01.03.0020.007059%
The 1th Page    1 2 3 4 5    Next   Last    Total 6 Pages